Glycoprotein 130 receptor signaling mediates α-cell dysfunction in a rodent model of type 2 diabetes

Diabetes

Volumn 63, Issue 9, 2014, Pages 2984-2995

  Chow, Samuel Z ^a   Speck, Madeleine ^a   Yoganathan, Piriya ^a   Nackiewicz, Dominika ^a   Hansen, Ann Maria ^b   Ladefoged, Mette ^b   Rabe, Björn ^c   Rose John, Stefan ^c   Voshol, Peter J ^d   Lynn, Francis C ^a   Herrera, Pedro L ^e   Müller, Werner ^f   Ellingsgaard, Helga ^g   Ehses, Jan A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NOVO NORDISK A S   (Denmark)

^c UNIVERSITY OF KIEL   (Germany)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF GENEVA   (Switzerland)

^f UNIVERSITY OF MANCHESTER   (United Kingdom)

^g UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN 130 RECEPTOR; INSULIN; INTERLEUKIN 6; RECEPTOR; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DIET RESTRICTION; GLUCAGON RELEASE; GLUCOSE TOLERANCE; HYPERGLYCEMIA; INFLAMMATION; INSULIN SENSITIVITY; LIPID DIET; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS;

ANIMALS; CYTOKINE RECEPTOR GP130; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; GLUCAGON; GLUCAGON-SECRETING CELLS; INTERLEUKIN-6; MALE; MICE; MICE, KNOCKOUT; PHOSPHORYLATION; RATS; STAT3 TRANSCRIPTION FACTOR;

EID: 84906719512     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db13-1121     Document Type: Article

References (49)

1. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356:1517-1526
2. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011;11:98-107
3. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000;85:4053-4059
4. Baron AD, Schaeffer L, Shragg P, Kolterman OG. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 1987;36:274-283
5. Dunning BE, Gerich JE. The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 2007;28:253-283
6. Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover. J Clin Invest 2012;122:4-12
7. Ehses JA, Perren A, Eppler E, et al. Increased number of islet-Associated macrophages in type 2 diabetes. Diabetes 2007;56:2356-2370
8. Richardson SJ, Willcox A, Bone AJ, Foulis AK, Morgan NG. Islet-Associated macrophages in type 2 diabetes. Diabetologia 2009;52:1686-1688
9. Böni-Schnetzler M, Thorne J, Parnaud G, et al. Increased interleukin (IL)- 1beta messenger ribonucleic acid expression in beta -cells of individuals with type 2 diabetes and regulation of IL-1beta in human islets by glucose and autostimulation. J Clin Endocrinol Metab 2008;93:4065-4074
10. Igoillo-Esteve M, Marselli L, Cunha DA, et al. Palmitate induces a proinflammatory response in human pancreatic islets that mimics CCL2 expression by beta cells in type 2 diabetes. Diabetologia 2010;53:1395-1405
11. Lee E, Ryu GR, Ko SH, et al. Antioxidant treatment may protect pancreatic beta cells through the attenuation of islet fibrosis in an animal model of type 2 diabetes. Biochem Biophys Res Commun 2011;414:397-402
12. Homo-Delarche F, Calderari S, Irminger JC, et al. Islet inflammation and fibrosis in a spontaneous model of type 2 diabetes, the GK rat. Diabetes 2006;55: 1625-1633
13. Eguchi K, Manabe I, Oishi-Tanaka Y, et al. Saturated fatty acid and TLR signaling link β cell dysfunction and islet inflammation. Cell Metab 2012;15:518-533
14. Jones HB, Nugent D, Jenkins R. Variation in characteristics of islets of Langerhans in insulin-resistant, diabetic and non-diabetic-rat strains. Int J Exp Pathol 2010;91:288-301
15. Masters SL, Dunne A, Subramanian SL, et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1b in type 2 diabetes. Nat Immunol 2010;11:897-904
16. Youm YH, Adijiang A, Vandanmagsar B, Burk D, Ravussin A, Dixit VD. Elimination of the NLRP3-ASC inflammasome protects against chronic obesityinduced pancreatic damage. Endocrinology 2011;152:4039-4045
17. Chentouf M, Dubois G, Jahannaut C, et al. Excessive food intake, obesity and inflammation process in Zucker fa/fa rat pancreatic islets. PLoS ONE 2011;6: E22954
18. Nicol LE, Grant WF, Comstock SM, et al. Pancreatic inflammation and increased islet macrophages in insulin-resistant juvenile primates [published correction appears in J Endocrinol 2013;218:X1]. J Endocrinol 2013;217:207-213
19. Rohrer S, Menge BA, Grüber L, et al. Impaired crosstalk between pulsatile insulin and glucagon secretion in prediabetic individuals. J Clin Endocrinol Metab 2012;97:E791-E795
20. Ehses JA, Lacraz G, Giroix MH, et al. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat. Proc Natl Acad Sci U S A 2009;106:13998-14003
21. Ellingsgaard H, Ehses JA, Hammar EB, et al. Interleukin-6 regulates pancreatic alpha-cell mass expansion. Proc Natl Acad Sci U S A 2008;105:13163-13168
22. Ellingsgaard H, Hauselmann I, Schuler B, et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat Med 2011;17:1481-1489
23. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro- and antiinflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011;1813:878-888
24. Mahdi T, Hänzelmann S, Salehi A, et al. Secreted frizzled-related protein 4 reduces insulin secretion and is overexpressed in type 2 diabetes. Cell Metab 2012;16:625-633
25. Betz UA, Bloch W, van den Broek M, et al. Postnatally induced inactivation of gp130 in mice results in neurological, cardiac, hematopoietic, immunological, hepatic, and pulmonary defects. J Exp Med 1998;188:1955-1965
26. Herrera PL. Adult insulin- and glucagon-producing cells differentiate from two independent cell lineages. Development 2000;127:2317-2322
27. Westwell-Roper C, Dai DL, Soukhatcheva G, et al. IL-1 blockade attenuates islet amyloid polypeptide-induced proinflammatory cytokine release and pancreatic islet graft dysfunction. J Immunol 2011;187:2755-2765
28. Ladefoged M, Buschard K, Hansen AM. Increased expression of toll-like receptor 4 and inflammatory cytokines, interleukin-6 in particular, in islets from a mouse model of obesity and type 2 diabetes. APMIS 2013;121:531-538
29. Ribaux P, Ehses JA, Lin-Marq N, et al. Induction of CXCL1 by extracellular matrix and autocrine enhancement by interleukin-1 in rat pancreatic beta-cells. Endocrinology 2007;148:5582-5590
30. Peters M, Blinn G, Solem F, Fischer M, Meyerzum Büschenfelde KH, Rose- John S. In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6. J Immunol 1998;161:3575-3581
31. Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in crohn disease and experimental colitis in vivo. Nat Med 2000;6:583-588
32. Voshol PJ, Jong MC, Dahlmans VE, et al. In muscle-specific lipoprotein lipase-overexpressing mice, muscle triglyceride content is increased without inhibition of insulin-stimulated whole-body and muscle-specific glucose uptake. Diabetes 2001;50:2585-2590
33. Huynh FK, Levi J, Denroche HC, et al. Disruption of hepatic leptin signaling protects mice from age- and diet-related glucose intolerance. Diabetes 2010;59: 3032-3040
34. Levi J, Gray SL, Speck M, et al. Acute disruption of leptin signaling in vivo leads to increased insulin levels and insulin resistance. Endocrinology 2011;152: 3385-3395
35. Ehses JA, Meier DT, Wueest S, et al. Toll-like receptor 2-deficient mice are protected from insulin resistance and beta cell dysfunction induced by a high-fat diet. Diabetologia 2010;53:1795-1806
36. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25:402-408
37. Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011;121:3375-3383
38. Lu J, Herrera PL, Carreira C, et al. Alpha cell-specific Men1 ablation triggers the transdifferentiation of glucagon-expressing cells and insulinoma development. Gastroenterology 2010;138:1954-1965
39. Müller WA, Faloona GR, Aguilar-Parada E, Unger RH. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 1970;283:109-115
40. Kawamori D, Welters HJ, Kulkarni RN. Molecular pathways underlying the pathogenesis of pancreatic alpha-cell dysfunction. Adv Exp Med Biol 2010;654: 421-445
41. Johansson U, Olsson A, Gabrielsson S, Nilsson B, Korsgren O. Inflammatory mediators expressed in human islets of Langerhans: implications for islet transplantation. Biochem Biophys Res Commun 2003;308:474-479
42. Westwell-Roper CY, Ehses JA, Verchere CB. Resident macrophages mediate islet amyloid polypeptide-induced islet IL-1b production and beta cell dysfunction. Diabetes. 12 November 2013 [Epub ahead of print]
43. Patel DG. Role of parasympathetic nervous system in glucagon response to insulin-induced hypoglycemia in normal and diabetic rats. Metabolism 1984;33: 1123-1127
44. Lamy CM, Sanno H, Labouèbe G, et al. Hypoglycemia-Activated GLUT2 Neurons of the Nucleus Tractus Solitarius Stimulate Vagal Activity and Glucagon Secretion. Cell Metab 2014;19:527-538
45. Tweedell A, Mulligan KX, Martel JE, Chueh FY, Santomango T, McGuinness OP. Metabolic response to endotoxin in vivo in the conscious mouse: role of interleukin-6. Metabolism 2011;60:92-98
46. Lundblad TM, Coldren A, Brissova M, Chukwuma V, Ansari T, McGuinness OP. Interleukin-6 amplifies adrenergic-dependent glucagon secretion. Diabetes 2012;61:A477
47. Fernández-Millán E, de Toro-Martín J, Lizárraga-Mollinedo E, Escrivá F, Álvarez C. Role of endogenous IL-6 in the neonatal expansion and functionality of Wistar rat pancreatic alpha cells. Diabetologia 2013;56:1098-1107
48. Habener JF, Stanojevic V. Alpha cells come of age. Trends Endocrinol Metab 2013;24:153-163
49. Spijker HS, Ravelli RB, Mommaas-Kienhuis AM, et al. Conversion of mature human b-cells into glucagon-producing a-cells. Diabetes 2013;62:2471-2480